Dr Shore (Carolina Urologic Research Center, Myrtle Beach, USA) and Dr Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss new treatment options for metastatic prostate cancer for ecancertv at ASCO GU 2016.
They discuss an open-label phase II study which evaluated the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases.
They also consider a new option arising for those CRPC patients who have become resistant to abiraterone and enzalutamide - the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Негізгі бет New treatment options in metastatic prostate cancer
Пікірлер